aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-12-04 14:00Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the failure of a key study [1][2]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements while concealing material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [1]. - The EFZO-FIT study did not meet its primary endpoint, which was announced on September 15, 2025, leading to a drastic stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [1]. - The company plans to engage with the FDA to determine the next steps following the disappointing study results [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline of December 8, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].